Brief: EMA'S CHMP Grants Marketing Authorisation For AbbVie's Ovarian Cancer Therapy Elahere

Apellis Pharmaceuticals

20/09/2024 12:11

Sept 20 (Reuters) - 
  
    * EMA'S CHMP: GRANTING MARKETING AUTHORISATION FOR ELAHERE
FOR
TREATMENT OF ADULTS WITH OVARIAN CANCER, FALLOPIAN TUBE CANCER,
PRIMARY PERITONEAL CANCER
    * EMA'S CHMP: POSITIVE OPINIONS TO UPDATE COMPOSITION OF
MRNA
VACCINE SPIKEVAX1, TO TARGET SARS-COV-2 JN.1 VARIANT, COMIRNATY
FOR KP.2 SUBVARIANT
    * EMA'S CHMP: CONFIRMED INITIAL RECOMMENDATION TO REFUSE
GRANTING
OF MARKETING AUTHORISATION FOR SYFOVRE (PEGCETACOPLAN)
    * EMA'S CHMP: ADOPTED POSITIVE OPINION FOR PENBRAYA, VACCINE
INDICATED FOR IMMUNISATION AGAINST INVASIVE DISEASE CAUSED BY
NEISSERIA MENINGITIDIS
    * EMA'S CHMP: POSITIVE OPINIONS FOR AFQLIR (AFLIBERCEPT) AND
OPUVIZ (AFLIBERCEPT)

Source text for Eikon:  ID: 
Further company coverage:  ABBV.N 

 ((Reuters.Briefs@thomsonreuters.com;))